Abstract: The application relates to the production of RNA of interest, more specifically of messenger RNA of interest or of long non-coding RNA of interest, by yeasts with recombinant pseudo-viral particles. The recombinant yeasts have been genetically modified in order to produce the RNA of interest in the form of a complex, particularly in the form of recombinant pseudo-viral particles. These recombinant pseudo-viral particles are produced from certain elements of yeast Ty retrotransposon, but do not retrotranscribe the RNA that they contain. Thus, the application relates to the components that are thus capable of being implemented or produced, and particularly to the nucleic acid constructs, kits, bacteria cells, yeast cells, culture or transfection media containing them, as well as to a method for producing a pharmaceutical composition, particularly for medical applications, more specifically for vaccines, anti-tumour and pro-regenerative applications.

Abstract: Disclosed are new synthetic compounds that includes a lipid diether to which a sugar group is grafted via a PEG spacer, and to now liposomes including at least one of the compounds. In particular, new synthetic compounds of general formula (I) and to new liposomes including at least one of the compounds is disclosed, as well as new liposomes for use as vectors and/or adjuvants, especially for use in vaccines.

Abstract: The application relates to the production of RNA of interest, more specifically of messenger RNA of interest or of long non-coding RNA of interest, by yeasts with recombinant pseudo-viral particles. The recombinant yeasts have been genetically modified in order to produce the RNA of interest in the form of a complex, particularly in the form of recombinant pseudo-viral particles. These recombinant pseudo-viral particles are produced from certain elements of yeast Ty retrotransposon, but do not retrotranscribe the RNA that they contain. Thus, the application relates to the components that are thus capable of being implemented or produced, and particularly to the nucleic acid constructs, kits, bacteria cells, yeast cells, culture or transfection media containing them, as well as to a method for producing a pharmaceutical composition, particularly for medical applications, more specifically for vaccines, anti-tumour and pro-regenerative applications.

Abstract: A method for the in vitro production of DNA minicircles includes steps of: a) providing nicked double-stranded oligodeoxynucleotides bunt-ended substrates having at least one phosphorylated 5? end, b) performing a ligase-mediated circularization on a reaction mixture including the nicked double-stranded oligodeoxynucleotides substrates and a DNA bending protein, and c) obtaining DNA minicircles.

Abstract: A method for the in vitro production of DNA minicircles includes steps of: a) providing nicked double-stranded oligodeoxynucleotides bunt-ended substrates having at least one phosphorylated 5? end, b) performing a ligase-mediated circularization on a reaction mixture including the nicked double-stranded oligodeoxynucleotides substrates and a DNA bending protein, and c) obtaining DNA minicircles.

Abstract: The present invention relates to compositions comprising cationic polymers and their use in treating inflammatory lung diseases characterized by the recruitment of blood neutrophils in the airways favoring the formation of a thick, mucoid or mucopurulent sputum as found in cystic fibrosis.

Abstract: The invention relates to a static copolymer of linear polyethylenimine that comprises two monomer units of the following formulas I and II, in which R1 is a hydrogen atom or a C1-C6 alkyl radical, R2 is a hydrogen atom, a C1-C6 alkyl, aryl or aralkyl group, wherein the alkyl group is a C1-C6 one, n is a number between 1 and 99% of the total monomers, m is a number between 1 and 99% of the total monomers, and advantageously m+n=100%. The invention also relates to complexes of this copolymer with a nucleic acid, and to the use thereof in in vivo, in vitro or ex vivo gene transfection.

Abstract: The invention relates to a static copolymer of linear polyethylenimine that comprises two monomer units of the following formulas I and II, in which R1 is a hydrogen atom or a C1-C6 alkyl radical, R2 is a hydrogen atom, a C1-C6 alkyl, aryl or aralkyl group, wherein the alkyl group is a C1-C6 one, n is a number between 1 and 99% of the total monomers, m is a number between 1 and 99% of the total monomers, and advantageously m+n=100%. The invention also relates to complexes of this copolymer with a nucleic acid, and to the use thereof in in vivo, in vitro or ex vivo gene transfection.

Abstract: New co-lipids for use in combination with lipophilic compounds as nucleic acid vectors, for preparing a nucleic acid vector composition, and methods for introducing in vitro or in vivo a nucleic acid of interest into host cells, including a step of contacting host cells these nucleic acid vector compositions. The nucleic acid vector compositions have the combination (i) of a nucleic acid, cationic, lipophilic vector with (ii) a co-lipid. These nucleic acid vector compositions, in some embodiments, are present in the form of unilamellar or multilamellar vesicles.

Abstract: The complex has at least one negatively charged nucleic acid bonded to at least one positively charged polymeric conjugate The conjugate containing a polylysine formed from monomers having free NH3+ groups, and having at least 10% of the free NH3+ groups substituted by residues which can be protonated in a weakly acid medium causing destabilization of cell membranes. Optionally, some of the free NH3+ groups can be substituted by a molecule with a recognition signal by a cell membrane receptor. The free NH3+ groups of the said polylysine make up at least 30% of the monomers of the polymeric conjugate. The residue that causes the destabilization of cell membrane in weak acid of quinolines of the formula: where R1 is hydrogen, R2 is —(CH2)n13 CO2—H, X is hydrogen or chlorine and n is an integer from 1 to 10. The signal is a simple oside or a disaccharide or peptide.

Abstract: A compound consisting essentially of polylysine conjugated to non-charged residues and recognition signals wherein the free amino functions of said polylysine are substituted with non-charged residues and said recognition signals, which non-charged residues consist of gluconalactone and which recognition signals are at least one member of the group consisting of galactoside, mannoside, fucoside, Lewis.sup.x, Lewis.sup.b, oligomannoside, oligolactosamine saccharides and peptide ANP and said conjugated polylysine contains at least 30% unsubstituted free amino functions and a method of transfecting cultured cells.

Abstract: The invention concerns a complex between at least one negatively charged nucleic acid and at least one positively charged polymeric conjugate, the link between the nucleic acid and the polymeric conjugate being electrostatic in nature, the polymeric conjugate containing a polymer formed from monomer components having free NH.sub.3.sup.+ functions of the aforementioned components and being as follows:--the free NH.sub.3.sup.+ functions from the aforementioned components are substituted in a ratio of at least 10%, advantageously from 45% to 70%, particularly 60%, by noncharged residues leading to a reduction of positive charges in comparison to the same nonsubstituted polymeric conjugate, facilitating the release of nucleic acid by the dissociation of the complex,--the aforementioned residues possess in addition the following properties:.fwdarw.they contain at least one hydroxyl group,.fwdarw.they do not correspond to a recognition signal recognized by a cellular membrane receptor,--the free NH.sub.3.sup.